ALK and non-small cell lung carcinoma: Additionally, because a common (20–30% incidence) comorbidity in NSCLC patients is metastasis to the brain, which is enhanced (44–60% incidence) among patients with druggable oncogene drivers (EGFR, ALK) (54), it is of interest to investigate whether NOTCH inhibitors that cross the blood-brain barrier can prevent or reduce brain metastasis formation.